NAMS Valuation

NewAmsterdam Pharma Company NV

Add to Watchlist

Advanced Chart

23.420

-0.18(-0.763%)1D

Overview
Forecast
Valuation
Earnings

NAMS Relative Valuation

NAMS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAMS is overvalued; if below, it's undervalued.

Historical Valuation

NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 148.69 is considered Fairly compared with the five-year average of 3.23. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between 3.53 to 85.52 according to relative valuation methord.

Relative Value

Fair Zone

3.53-85.52

Current Price：23.95

Fair

-11.70

Trailing

Forward

-8.45

EV/EBITDA

NewAmsterdam Pharma Company NV. (NAMS) has a current EV/EBITDA of -8.45. The 5-year average EV/EBITDA is 3.15. The thresholds are as follows: Strongly Undervalued below -11.88, Undervalued between -11.88 and -4.36, Fairly Valued between 10.67 and -4.36, Overvalued between 10.67 and 18.18, and Strongly Overvalued above 18.18. The current Forward EV/EBITDA of -8.45 falls within the Undervalued range.

-7.23

EV/EBIT

NewAmsterdam Pharma Company NV. (NAMS) has a current EV/EBIT of -7.23. The 5-year average EV/EBIT is -4.21. The thresholds are as follows: Strongly Undervalued below -10.29, Undervalued between -10.29 and -7.25, Fairly Valued between -1.16 and -7.25, Overvalued between -1.16 and 1.88, and Strongly Overvalued above 1.88. The current Forward EV/EBIT of -7.23 falls within the Historic Trend Line -Fairly Valued range.

150.03

NewAmsterdam Pharma Company NV. (NAMS) has a current PS of 150.03. The 5-year average PS is 160.41. The thresholds are as follows: Strongly Undervalued below -269.47, Undervalued between -269.47 and -54.53, Fairly Valued between 375.34 and -54.53, Overvalued between 375.34 and 590.28, and Strongly Overvalued above 590.28. The current Forward PS of 150.03 falls within the Historic Trend Line -Fairly Valued range.

-12.93

P/OCF

NewAmsterdam Pharma Company NV. (NAMS) has a current P/OCF of -12.93. The 5-year average P/OCF is -7.82. The thresholds are as follows: Strongly Undervalued below -19.00, Undervalued between -19.00 and -13.41, Fairly Valued between -2.22 and -13.41, Overvalued between -2.22 and 3.37, and Strongly Overvalued above 3.37. The current Forward P/OCF of -12.93 falls within the Historic Trend Line -Fairly Valued range.

-11.50

P/FCF

NewAmsterdam Pharma Company NV. (NAMS) has a current P/FCF of -11.50. The 5-year average P/FCF is -6.69. The thresholds are as follows: Strongly Undervalued below -15.68, Undervalued between -15.68 and -11.18, Fairly Valued between -2.20 and -11.18, Overvalued between -2.20 and 2.29, and Strongly Overvalued above 2.29. The current Forward P/FCF of -11.50 falls within the Undervalued range.

NewAmsterdam Pharma Company NV (NAMS) has a current Price-to-Book (P/B) ratio of 3.41. Compared to its 3-year average P/B ratio of 3.29 , the current P/B ratio is approximately 3.61% higher. Relative to its 5-year average P/B ratio of 0.43, the current P/B ratio is about 686.18% higher. NewAmsterdam Pharma Company NV (NAMS) has a Forward Free Cash Flow (FCF) yield of approximately -5.36%. Compared to its 3-year average FCF yield of -5.99%, the current FCF yield is approximately -10.60% lower. Relative to its 5-year average FCF yield of -5.99% , the current FCF yield is about -10.60% lower.

3.41

P/B

Median3y

3.29

Median5y

0.43

-5.31

FCF Yield

Median3y

-5.99

Median5y

-5.99

Competitors Valuation Multiple

The average P/S ratio for NAMS's competitors is 34.70, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS) exhibits a P/S ratio of 150.03, which is 332.40% above the industry average. Given its robust revenue growth of 112.56%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NAMS.O

NewAmsterdam Pharma Company NV

Ligand Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

Mirum Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Loss

43.56%

2.54B

Performance Decomposition

Market capitalization of NAMS increased by 36.80% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 1.40M to 2.98M.

The secondary factor is the P/E Change, contributed 4.41%to the performance.

Overall, the performance of NAMS in the past 1 year is driven by Revenue Growth. Which is more sustainable.

112.56%

1.40M → 2.98M

Revenue Growth

-80.17%

-6.69K → -1.33K

Margin Expansion

4.41%

-12.22 → -12.76

P/E Change

36.80%